Phasediagnostics

About Phasediagnostics

Phase Scientific International Limited operates as a biotechnology company focused on diagnostics for early disease detection. The company was founded in 2015 by Dr. Ricky Chiu, who serves as the Chairman and CEO, as a spin-off from his bioengineering PhD research at the University of California, Los Angeles (UCLA). Initially backed by organizations like the Bill and Melinda Gates Foundation, the company first concentrated on early cancer detection before pivoting to develop rapid tests during the COVID-19 pandemic. Headquartered in Hong Kong, Phase Scientific maintains a cross-border presence with operations in Southern California and China's Greater Bay Area, allowing it to utilize regional strengths in research, manufacturing, and commercialization.

The core of the company's business is its proprietary PHASIFY™ technology, a liquid phase extraction method that concentrates and purifies target biomolecules like DNA and RNA from patient samples. This process increases the yield of biomarkers, such as circulating cell-free DNA (cfDNA), by more than tenfold compared to some industry standards, thereby enhancing the sensitivity of diagnostic tests. The technology is designed to make diagnostic testing more accessible, affordable, and accurate. A key application of PHASIFY™ is in urine-based liquid biopsies, which offer a non-invasive method for sample collection that can be done at home, shifting healthcare focus from treatment to prevention.

Phase Scientific generates revenue through the sale of diagnostic products and services across several health categories, including oncology, infectious diseases, and women's health. The company has commercialized over 30 products and distributed more than 100 million tests in over 30 countries. Its product lines include the INDICAID™ series of over-the-counter (OTC) and point-of-care (POC) rapid antigen tests for various infectious diseases. A notable product is the world's first urine-based HPV test for cervical cancer screening, which allows for at-home self-sampling. This test demonstrated 93.4% sensitivity in detecting high-grade precancerous lesions and cancer in a clinical study. The company serves a global market, with a strategic focus on accessing China's healthcare market from its Hong Kong base.